Geodon (Ziprasidone) for Posttraumatic Stress Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00208208 |
Recruitment Status :
Completed
First Posted : September 21, 2005
Last Update Posted : September 15, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Posttraumatic Stress Disorder Post-Traumatic Stress Disorder PTSD | Drug: Ziprasidone | Phase 4 |
PTSD is a common disorder with 10% lifetime prevalence among Americans. The major causes of PTSD are sexual assault, accidents, disasters Despite this public health burden, only two drugs, sertraline (Zoloft) and paroxetine (Paxil), are approved by the FDA for the treatment of PTSD. New options for the treatment of PTSD are much needed. Approximately half of patients with PTSD respond to Zoloft and Paxil. Many patients experience psychotic symptoms with PTSD, which may not respond to treatment to Zoloft and Paxil.
Though classified as an anxiety disorder in the DSM-IV, PTSD is accompanied by psychotic symptoms in almost half of patients (Butler et al 1996; Hamner et al 1999, Lindley et al 2000). Also, PTSD has an extensive comorbidity with major depressive disorder (Davis et al 2000). While Geodon is approved by the FDA in the United States for the treatment of psychosis, it has not been evaluated for the treatment of PTSD . A clinical trial of Geodon in PTSD will help delineate the potential antidepressant spectrum of efficacy of Geodon as well as its anxiolytic profile.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Diagnostic |
Official Title: | Geodon (Ziprasidone) for Posttraumatic Stress Disorder |
Study Start Date : | December 2002 |
Study Completion Date : | April 2005 |

- Response to ziprasidone or placebo (inactive drug) will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
- A secondary aim of the study is to measure effects on depression and anxiety symptoms in the same persons, using the HAM-A, HAM-D and the CGI. Quality of life will also be assessed using the QOLI.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Men & women with DSM-IV clinical diagnosis of PTSD who are able to attend weekly clinic appointments
- Age 19-64, not pregnant and either sterile or using a medically acceptable method of birth control
- A willingness and ability to provide competent signed informed consent
- A level of understanding sufficient to perform all tests and examinations required by the protocol (including fluency of spoken English)
Exclusion Criteria:
- Any diagnosis of schizophrenia or bipolar I disorder, or active substance dependence
- Unstable general medical condition or serious illness (e.g.. death or hospitalization is anticipated within one year), poor kidney function, liver function (defined as lab values ≥ three times the upper limit of the laboratory normal) and seizure disorders with the exception of childhood seizure disorders.
- Subjects with prior non-response to Geodon for the treatment of PTSD with an adequate trial
- Enrollment in any study drug within the last 30 days. Current pharmacotherapy is permitted, provided that the medication and dose have been stable for the past 90 days.
- Pregnancy or nursing
- Any subject judged clinically to be at serious suicidal risk in the opinion of the investigator

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00208208
United States, Nebraska | |
Creighton University Psychiatry and Research Center | |
Omaha, Nebraska, United States, 68131 |
Principal Investigator: | Frederick Petty, MD, PhD | Creighton University |
ClinicalTrials.gov Identifier: | NCT00208208 |
Other Study ID Numbers: |
2001-0261 Grant 2001-0261 |
First Posted: | September 21, 2005 Key Record Dates |
Last Update Posted: | September 15, 2006 |
Last Verified: | April 2005 |
Posttraumatic Stress Disorder Post-traumatic Stress Disorder PTSD Geodon Ziprasidone |
Disease Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Pathologic Processes Trauma and Stressor Related Disorders Mental Disorders Ziprasidone Serotonin Antagonists Serotonin Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents |